Coll Crespo Blas 4

What Happened

• Coll Crespo Blas, Chief Medical Officer of Structure Therapeutics (GPCR), received two equity awards on 2026-03-19: 75,897 restricted stock units (RSUs) and 93,984 derivative awards (reported as acquisitions at $0.00). The Form 4 was filed on 2026-03-23. The reported dollar amount for both grants is $0 because these are compensation awards (no cash paid at grant).

Key Details

• Transaction date: 2026-03-19; Form 4 filed: 2026-03-23 (timely — within two business days).
• Awards: 75,897 RSUs (footnote F2) and 93,984 derivative awards (footnotes F3/F4 indicate stock-option style terms).
• Price / cash: reported acquisition price $0.00 for both awards (compensation grants).
• Vesting for RSUs (F2): RSUs represent a contingent right to one Ordinary Share each and vest 1/4 annually on each anniversary of March 1, 2026, subject to continued service (i.e., annual 25% vesting).
• Derivative/option terms (F3/F4): exercise price per share equals fair market value on grant date; vesting: 1/4 on March 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to continued service.
• ADS note (F1): Ordinary Shares may be represented by American Depositary Shares (each ADS = 3 Ordinary Shares).
• Shares owned after the transaction: not provided in the excerpt of the filing.

Context

• These entries are awards (compensation), not open-market purchases or sales — common for new or ongoing executive compensation and not, by themselves, a buy/sell signal.
• The derivative award appears to be an option-style grant (exercise required later at a price tied to market value); exercise or sale would create a taxable/event and likely be reported separately if/when they occur.